Abstract 1982P
Background
KS, associated with human herpesvirus 8 (KSHV) infection, is a tumor originating from endothelial cells. As a common tumor associated with AIDS, KS is typically more aggressive in HIV-positive (HIV+) than in HIV-negative (HIV-) patients (pts). While antiretroviral therapy helps control KS in HIV+ pts, chemotherapy remains the first-line treatment (Tx) in advanced KS but is limited by modest responses and dose-limiting toxicities. The TME has been shown to play a critical role in KS development and progression. Here, we sought to understand the TME in KS, with a specific focus on the differences in HIV status.
Methods
Whole transcriptomic profiling was performed on 13 retrospective samples from 9 pts (HIV+: n = 6, HIV- n =3; mostly baseline, except 2 HIV- and 2 HIV+ pts had paired samples before and after Tx). A deconvolution algorithm Kassandra was used to predict cellular composition with pre-training on sarcoma samples, and EdgeR was used for differential expression analysis. TME subtypes were classified based on a previous study (Bagaev et al., 2021) assessing sarcoma-related gene expression patterns.
Results
All KS samples were enriched with endothelial cells and had characteristics of a typical sarcoma TME with an abundance of macrophages and normal amounts of B cells. Most HIV- pts had an Immune-Enriched, Non-fibrotic subtype, while HIV+ pts had immune-Enriched, Fibrotic or Fibrotic TMEs. Decreased angiogenic signatures were observed after Tx in HIV+ pts with paired samples. Expression levels of chemokines (CXCL2, CXCL8, CXCL11), chemokine receptors (CCR1-7, CXCR1-2), and CCL factors were higher in pre-Tx HIV- pts versus post-Tx and post-TX HIV+ pts versus pre-TX. PD-L1 and PD-L2 expressions were higher in HIV- pts before Tx and in HIV+ pts after Tx. In 3 HIV- and 2 HIV+ pts, for whom TCR.
Conclusions
Our results showed distinct transcriptomic features and TMEs between HIV+ and HIV- KS in responses to Tx. Future larger cohorts and research into the unique T cell clonotypes may help yield novel therapeutic avenues in KS.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
BostonGene, Corp. and Albert Einstein College of Medicine.
Funding
BostonGene, Corp.
Disclosure
A. Sevkoplyas, S. Podsvirova, A. Tyshevich, K. Zornikova, N. Shin, N. Kotlov, E. Postovalova: Financial Interests, Institutional, Full or part-time Employment: BostonGene, Corp.; Financial Interests, Institutional, Stocks/Shares: BostonGene, Corp.. L. Paoluzzi: Financial Interests, Institutional, Full or part-time Employment: Regeneron; Financial Interests, Institutional, Stocks/Shares: Regeneron. All other authors have declared no conflicts of interest.
Resources from the same session
1970P - Metastatic chondrosarcoma, patterns of care and outcomes of patients in a real-life setting: The Metabone national observational study
Presenter: coline ducrot
Session: Poster session 15
1971P - Metastatic osteosarcoma, patterns of care and outcomes of patients in a real-life setting: The Metabone national observational study
Presenter: Mathilde Reich
Session: Poster session 15
1972P - Molecular mechanism study of recurrence/metastasis for Enneking IIb osteosarcoma
Presenter: Junqiang Yin
Session: Poster session 15
1975P - Systemic therapy for KIT/PDGFRA wild-type GIST
Presenter: Mehdi Brahmi
Session: Poster session 15
1976P - Financial difficulties experienced by gastrointestinal stromal tumor (GIST) patients in the Netherlands: Data from a cross-sectional multicenter study
Presenter: Deborah van de Wal
Session: Poster session 15
1977P - A registry-based analysis of the projected genomic landscape among unclassified KIT/PDGFRA wildtype mutations in patients with gastrointestinal stromal tumors
Presenter: Jerry Call
Session: Poster session 15
1978P - Identification of SDH-deficient GIST increases after the implementation of diagnostic algorithm in Life Raft Group (LRG) patient registry data
Presenter: Denisse Evans
Session: Poster session 15
1979P - phase I trial of pembrolizumab in HIV-associated Kaposi sarcoma (KS)
Presenter: Kathryn Lurain
Session: Poster session 15
1980P - Artificial intelligence analysis shows enhanced CCNG1 expression in sarcoma tumors, a novel biomarker for DeltaRex-G tumor targeted retrovector encoding a CCNG1 inhibitor gene
Presenter: Sant Chawla
Session: Poster session 15